Survival Cost and Diverse Molecular Mechanisms of Magnaporthe oryzae Isolate Resistance to Epoxiconazole

Plant Disease ◽  
2020 ◽  
pp. PDIS-02-20-0393
Author(s):  
Meng Cai ◽  
Jianqiang Miao ◽  
Fengping Chen ◽  
Botao Li ◽  
Xili Liu
Keyword(s):  
Amino Acid ◽  
Magnaporthe Oryzae ◽  
Rice Blast ◽  
Molecular Mechanisms ◽  
Binding Pocket ◽  
Cross Resistance ◽  
Low Resistance ◽  
Excellent Control ◽  
Dmi Resistance

Rice blast caused by Magnaporthe oryzae is one of the most destructive diseases on rice worldwide. Epoxiconazole is a 14α-demethylation inhibitor (DMI) with excellent control on rice blast; to date, no resistant isolates have been observed in the field. Four mutants resistant to epoxiconazole were generated from three parental isolates via fungicide adaptation. Resistance was stable after 10 weekly consecutive transfers on fungicide-free medium. Three parameters, including growth rate, sporulation in vitro, and aggressiveness, were significantly lower for mutants compared with their parental isolates, with the exception of the low-resistance isolate. Sporulation and aggressiveness were negatively correlated with effective concentration values for 50% inhibition of mycelial growth for parental isolates and mutants (P < 0.05). Cross-resistance was found between epoxiconazole and prochloraz (ρ = 0.863, P = 0.000) or difenoconazole (ρ = 0.861, P = 0.000). The resistance factor for mutants was positively correlated with the relative expression of MoCYP51A in epoxiconazole treatment (r = 0.977, P = 0.02). In addition, two putative amino acid substitutions in MoCYP51A were found in two resistant mutants: Y126F in the high-resistance mutant and I125L in the low-resistance mutant. Mutation Y126F reduced the affinity of MoCYP51A with epoxiconazole, whereas I125L was not in the binding pocket of epoxiconazole. No amino acid change or overexpression in MoCYP51B was found in any of the mutants studied. To our knowledge, this is the first study to report DMI resistance observed in M. oryzae. The survival cost of M. oryzae resistance to epoxiconazole might be the reason why DMI resistance has not yet emerged in field populations worldwide.

scholarly journals Lessons in effector and NLR biology of plant-microbe systems

2017 ◽  
Author(s):  
Aleksandra Białas ◽  
Erin K. Zess ◽  
Juan Carlos De la Concepcion ◽  
Marina Franceschetti ◽  
Helen G. Pennington ◽  
...  
Keyword(s):  
Plant Physiology ◽  
Magnaporthe Oryzae ◽  
Rice Blast ◽  
Molecular Mechanisms ◽  
Rice Blast Fungus ◽  
Leucine Rich Repeat ◽  
Nucleotide Binding Domain ◽  
Immune Receptors ◽  
Microbe Interactions ◽  
Host Infection

A diversity of plant-associated organisms secrete effectors—proteins and metabolites that modulate plant physiology to favor host infection and colonization. However, effectors can also activate plant immune receptors, notably nucleotide-binding domain and leucine-rich repeat-containing (NLR) proteins, enabling plants to fight off invading organisms. This interplay between effectors, their host targets, and the matching immune receptors is shaped by intricate molecular mechanisms and exceptionally dynamic coevolution. In this article, we focus on three effectors, AVR-Pik, AVR-Pia, and AVR-Pii, from the rice blast fungus Magnaporthe oryzae (syn. Pyricularia oryzae), and their corresponding rice NLR immune receptors, Pik, Pia, and Pii, to highlight general concepts of plant-microbe interactions. We draw 12 lessons in effector and NLR biology that have emerged from studying these three little effectors and are broadly applicable to other plant-microbe systems.

Target site–based penoxsulam resistance in barnyardgrass (Echinochloa crus-galli) from China

Weed Science ◽  
2019 ◽  
Vol 67 (3) ◽  
pp. 281-287 ◽  
Author(s):  
Jiapeng Fang ◽  
Tingting Liu ◽  
Yuhua Zhang ◽  
Jun Li ◽  
Liyao Dong
Keyword(s):  
Amino Acid ◽  
Amino Acid Sequence ◽  
Acetolactate Synthase ◽  
Target Site ◽  
Cross Resistance ◽  
Predicted Amino Acid Sequence ◽  
Sequence Analyses ◽  
Als Inhibitors ◽  
Higher Sensitivity

AbstractBarnyardgrass [Echinochloa crus-galli (L.) P. Beauv.] is acknowledged to be the most troublesome weed in rice fields in Anhui and Jiangsu provinces of China. It cannot be effectively controlled using certain acetolactate synthase (ALS)-inhibiting herbicides, including penoxsulam. Echinochloa crus-galli samples with suspected resistance to penoxsulam were collected to identify the target site–based mechanism underlying this resistance. Populations AXXZ-2 and JNRG-2 showed 33- and 7.3-fold resistance to penoxsulam, respectively, compared with the susceptible JLGY-3 population. Cross-resistance to other ALS inhibitors was reported in AXXZ-2 but not in JNRG-2, and occasionally showed higher sensitivity than JLGY-3. In vitro ALS activity assays revealed that penoxsulam concentrations required to inhibit 50% of ALS activity were 11 and 5.2 times greater in AXXZ-2 and JNRG-2, respectively, than in JLGY-3. DNA and predicted amino acid sequence analyses of ALS revealed Ala-205-Val and Ala-122-Gly substitutions in AXXZ-2 and JNRG-2, respectively. Our results indicate that these substitutions in ALS are at least partially responsible for resistance to penoxsulam.

scholarly journals Transglutaminase 5 is regulated by guanine–adenine nucleotides1

2004 ◽  
Vol 381 (1) ◽  
pp. 313-319 ◽  
Author(s):  
Eleonora CANDI ◽  
Andrea PARADISI ◽  
Alessandro TERRINONI ◽  
Valentina PIETRONI ◽  
Sergio ODDI ◽  
...  
Keyword(s):  
Amino Acid ◽  
Three Dimensional ◽  
Binding Pocket ◽  
Cross Linking ◽  
Bifunctional Enzyme ◽  
Amino Acid Sequence Alignment ◽  
Gtp Binding ◽  
Epidermal Tissue ◽  
Isopeptide Bonds

Transglutaminases (TGases) are Ca2+-dependent enzymes capable of catalysing transamidation of glutamine residues to form intermolecular isopeptide bonds. Nine distinct TGases have been described in mammals, and two of them (types 2 and 3) are regulated by GTP/ATP. TGase2 hydrolyses GTP and is therefore a bifunctional enzyme. In the present study, we report that TGase5 is also regulated by nucleotides. We have identified the putative TGase5 GTP-binding pocket by comparative amino acid sequence alignment and homology-derived three-dimensional modelling. GTP and ATP inhibit TGase5 cross-linking activity in vitro, and Ca2+ is capable of completely reversing this inhibition. In addition, TGase5 mRNA is not restricted to epidermal tissue, but is also present in different adult and foetal tissues, suggesting a role for TGase5 outside the epidermis. These results reveal the reciprocal actions of Ca2+ and nucleotides with respect to TGase5 activity. Taken together, these results indicate that TGases are a complex family of enzymes regulated by calcium, with at least three of them, namely TGase2, TGase3 and TGase5, also being regulated by ATP and GTP.

scholarly journals Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance

mSphere ◽  
2018 ◽  
Vol 3 (6) ◽  
Author(s):  
Csaba Papp ◽  
Katica Kocsis ◽  
Renáta Tóth ◽  
László Bodai ◽  
Jesse R. Willis ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Amino Acid ◽  
Candida Parapsilosis ◽  
Hot Spot ◽  
Abiotic Stress Tolerance ◽  
Acquired Resistance ◽  
Cross Resistance ◽  
First Line ◽  
Content Type

ABSTRACT Candida species are a major cause of life-threatening bloodstream infections worldwide. Although Candida albicans is responsible for the vast majority of infections, the clinical relevance of other Candida species has also emerged over the last twenty years. This shift might be due in part to changes in clinical guidelines, as echinocandins became the first line of therapeutics for the treatment. Candida parapsilosis is an emerging non-albicans Candida species that exhibits lower susceptibility levels to these drugs. Candida species frequently display resistance to echinocandins, and the mechanism for this is well-known in C. albicans and Candida glabrata, where it is mediated by amino acid substitutions at defined locations of the β-1,3-glucan synthase, Fks1p. In C. parapsilosis isolates, Fks1p harbors an intrinsic amino acid change at position 660 of the hot spot 1 (HS1) region, which is thought to be responsible for the high MIC values. Less is known about acquired substitutions in this species. In this study, we used directed evolution experiments to generate C. parapsilosis strains with acquired resistance to caspofungin, anidulafungin, and micafungin. We showed that cross-resistance was dependent on the type of echinocandin used to generate the evolved strains. During their characterization, all mutant strains showed attenuated virulence in vivo and also displayed alterations in the exposure of inner cell wall components. The evolved strains harbored 251 amino acid changes, including three in the HS1, HS2, and HS3 regions of Fks1p. Altogether, our results demonstrate a direct connection between acquired antifungal resistance and virulence of C. parapsilosis. IMPORTANCE Candida parapsilosis is an opportunistic fungal pathogen with the ability to cause infections in immunocompromised patients. Echinocandins are the currently recommended first line of treatment for all Candida species. Resistance of Candida albicans to this drug type is well characterized. C. parapsilosis strains have the lowest in vitro susceptibility to echinocandins; however, patients with such infections typically respond well to echinocandin therapy. There is little knowledge of acquired resistance in C. parapsilosis and its consequences on other characteristics such as virulence properties. In this study, we aimed to dissect how acquired echinocandin resistance influences the pathogenicity of C. parapsilosis and to develop explanations for why echinocandins are clinically effective in the setting of acquired resistance.

scholarly journals Compensatory Substitutions in the HIV-1 Capsid Reduce the Fitness Cost Associated with Resistance to a Capsid-Targeting Small-Molecule Inhibitor

2014 ◽  
Vol 89 (1) ◽  
pp. 208-219 ◽  
Author(s):  
Jiong Shi ◽  
Jing Zhou ◽  
Upul D. Halambage ◽  
Vaibhav B. Shah ◽  
Mallori J. Burse ◽  
...  
Keyword(s):  
Amino Acid ◽  
Small Molecule ◽  
Therapeutic Target ◽  
Binding Pocket ◽  
Host Protein ◽  
Viral Capsid ◽  
Inhibitory Protein ◽  
Hiv 1 ◽  
Ca Protein

ABSTRACTThe HIV-1 capsid plays multiple roles in infection and is an emerging therapeutic target. The small-molecule HIV-1 inhibitor PF-3450074 (PF74) blocks HIV-1 at an early postentry stage by binding the viral capsid and interfering with its function. Selection for resistance resulted in accumulation of five amino acid changes in the viral CA protein, which collectively reduced binding of the compound to HIV-1 particles. In the present study, we dissected the individual and combinatorial contributions of each of the five substitutions Q67H, K70R, H87P, T107N, and L111I to PF74 resistance, PF74 binding, and HIV-1 infectivity. Q67H, K70R, and T107N each conferred low-level resistance to PF74 and collectively conferred strong resistance. The substitutions K70R and L111I impaired HIV-1 infectivity, which was partially restored by the other substitutions at positions 67 and 107. PF74 binding to HIV-1 particles was reduced by the Q67H, K70R, and T107N substitutions, consistent with the location of these positions in the inhibitor-binding pocket. Replication of the 5Mut virus was markedly impaired in cultured macrophages, reminiscent of the previously reported N74D CA mutant. 5Mut substitutions also reduced the binding of the host protein CPSF6 to assembled CA complexesin vitroand permitted infection of cells expressing the inhibitory protein CPSF6-358. Our results demonstrate that strong resistance to PF74 requires accumulation of multiple substitutions in CA to inhibit PF74 binding and compensate for fitness impairments associated with some of the sequence changes.IMPORTANCEThe HIV-1 capsid is an emerging drug target, and several small-molecule compounds have been reported to inhibit HIV-1 infection by targeting the capsid. Here we show that resistance to the capsid-targeting inhibitor PF74 requires multiple amino acid substitutions in the binding pocket of the CA protein. Three changes in CA were necessary to inhibit binding of PF74 while maintaining viral infectivity. Replication of the PF74-resistant HIV-1 mutant was impaired in macrophages, likely owing to altered interactions with host cell factors. Our results suggest that HIV-1 resistance to capsid-targeting inhibitors will be limited by functional constraints on the viral capsid protein. Therefore, this work enhances the attractiveness of the HIV-1 capsid as a therapeutic target.

Molecular mechanisms associated with the resistance of Rhizoctonia solani AG-4 isolates to the succinate dehydrogenase inhibitor, thifluzamide

2021 ◽  
Author(s):  
Can Zhao ◽  
Yuting Li ◽  
Zhijian Liang ◽  
Lihong Gao ◽  
Chenggui Han ◽  
...  
Keyword(s):  
Succinate Dehydrogenase ◽  
Molecular Mechanisms ◽  
Major Facilitator Superfamily ◽  
Cross Resistance ◽  
Active Efflux ◽  
Fitness Evaluation ◽  
Reverse Transcription Pcr ◽  
Major Facilitator ◽  
Median Effective Concentration

Thifluzamide, a succinate dehydrogenase (SDH) inhibitor, possesses high activity against Rhizoctonia. In this study, 144 R. solani AG-4 (4HGI, 4HGII, and 4HGIII) isolates, the predominate pathogen associated with sugar beet seedling damping-off, were demonstrated to be sensitive to thifluzamide with a calculated mean median effective concentration of 0.0682 ± 0.0025 μg/mL. Thifluzamide-resistant isolates were generated using fungicide-amended media, resulting in four AG-4HGI isolates and eight AG-4HGII isolates with stable resistance and almost no loss in fitness. Evaluation of cross-resistance of the twelve thifluzamide-resistant isolates and their corresponding parental-sensitive isolates revealed a moderately positive correlation between thifluzamide resistance and the level of resistance to eight other fungicides from three groups, the exception being fludioxonil. An active efflux of fungicide through ATP-binding cassette and major facilitator superfamily transporters was found to be correlated to the resistance of R. solani AG-4HGII isolates to thifluzamide based on RNA-sequencing and quantitative reverse transcription-PCR analyses. Sequence analysis of sdhA, sdhB, sdhC, and sdhD revealed replacement of isoleucine by phenylalanine at position 61 in SDHC in nine of the twelve generated thifluzamide-resistant isolates. No other mutations were found in any of the other genes. Collectively, the data indicate that the active efflux of fungicide and a point mutation in sdhC may contribute to the resistance of R. solani AG-4HGI and AG-4HGII isolates to thifluzamide in vitro. This is the first characterization of the potential molecular mechanism associated with the resistance of R. solani AG-4 isolates to thifluzamide, and provides practical guidance for the use of this fungicide.

Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3522-3522
Author(s):  
Jennifer Kahler ◽  
Maureen Dougher ◽  
Jia Lu ◽  
Jane Xu ◽  
Tasneem Kausar ◽  
...  
Keyword(s):  
Cell Lines ◽  
Molecular Mechanisms ◽  
Crosslinking Agent ◽  
Standard Of Care ◽  
Cross Resistance ◽  
Continuous Exposure ◽  
Next Generation ◽  
Multidrug Resistance Proteins ◽  
Clinical Resistance

Abstract Gemtuzumab ozogamicin (GO) is an FDA-approved antibody-drug conjugate that has shown clinical benefit in acute myeloid leukemia (AML) patients but has been voluntarily withdrawn from the market in the US. GO targets CD33 on AML tumor cells and delivers its cytotoxic payload, namely calicheamicin. Despite promising initial responses to GO, many patients relapsed while on therapy, and the development of clinical resistance to GO hampers its effectiveness. Initial investigations into the mechanisms responsible for clinical resistance to GO implicated the activity of multidrug resistance proteins (MDR) as a major contributor to the lack of clinical efficacy. To better understand the molecular mechanisms that may drive resistance to the payload used in GO, as well as standard of care agents in AML, we created calicheamicin-resistant and cytarabine-resistant AML cell lines. HL60 cells were continuously exposed to increasing concentrations of calicheamicin or cytarabine until resistant populations emerged. Calicheamicin-resistant HL60 (HL60-CAL-R) cells are ~40-fold resistant to calicheamicin and cytarabine-resistant HL60 (HL60-CYTAR-R) are ~2000- fold resistant to cytarabine compared to their isogenic parental counterparts as determined by in vitro cytotoxicity assays. Initial model characterization of HL60-CAL-R suggests that continuous exposure to calicheamicin induces the acquisition of a chemo-resistant phenotype highlighted by increased expression of MDR1 and MRP1/2. Furthermore, functional assays by flow cytometry revealed high levels of efflux activity in MDR1 and MRP1/2, but not BCRP, in HL60-CAL-R as compared to parental HL60. HL60-CAL-R could be re-sensitized to calicheamicin with the addition of verapamil (MDR1 inhibitor) or reversan (MDR1 and MRP1/2 inhibitor). HL60-CAL-R shows cross-resistance to daunorubicin (MDR1 substrate), but not cytarabine (non-MDR1 substrate), supporting MDR1 upregulation as one major mechanism of resistance to calicheamicin in this cell line. HL60-CAL-R cells are also cross-resistant to GO. In contrast, HL60-CYTAR-R do not have an induction of MDR1 and MRP1/2 protein levels or activity and retain sensitivity to GO in vitro and in vivo. Initial RNA-Seq profiling of HL60-CYTAR-R cells suggest they have decreased DCK expression, the loss of which was previously shown to mediate cytarabine resistance in other models. Intriguingly, HL60-CAL-R and HL60-CYTAR-R cells retained sensitivity to a proprietary next-generation DNA alkylating- and crosslinking- agent being developed at Pfizer, cyclopropylpyrrolo[e]indolone (CPI). These data demonstrate the utility of generating and characterizing drug-resistant cell lines to uncover clinically relevant mechanisms of resistance and identify next-generation compounds that can overcome them. Disclosures Kahler: Pfizer: Employment. Dougher:Pfizer: Employment. Lu:Pfizer: Other: Ex-Pfizer employee. Xu:Pfizer: Employment. Kausar:Pfizer: Other: Ex-Pfizer Employee. Lemon:Pfizer: Employment. Zhong:Pfizer: Employment. Lucas:Pfizer: Employment. Sung:Pfizer: Employment. Sapra:Pfizer: Employment, Equity Ownership.

scholarly journals CD98hc (SLC3A2) regulation of skin homeostasis wanes with age

2013 ◽  
Vol 210 (1) ◽  
pp. 173-190 ◽  
Author(s):  
Etienne Boulter ◽  
Soline Estrach ◽  
Aurélia Errante ◽  
Catherine Pons ◽  
Laurence Cailleteau ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Amino Acid ◽  
Molecular Mechanisms ◽  
Skin Aging ◽  
Amino Acid Transporters ◽  
Appreciable Effect ◽  
Nucleotide Exchange ◽  
Aged Skin

Skin aging is linked to reduced epidermal proliferation and general extracellular matrix atrophy. This involves factors such as the cell adhesion receptors integrins and amino acid transporters. CD98hc (SLC3A2), a heterodimeric amino acid transporter, modulates integrin signaling in vitro. We unravel CD98hc functions in vivo in skin. We report that CD98hc invalidation has no appreciable effect on cell adhesion, clearly showing that CD98hc disruption phenocopies neither CD98hc knockdown in cultured keratinocytes nor epidermal β1 integrin loss in vivo. Instead, we show that CD98hc deletion in murine epidermis results in improper skin homeostasis and epidermal wound healing. These defects resemble aged skin alterations and correlate with reduction of CD98hc expression observed in elderly mice. We also demonstrate that CD98hc absence in vivo induces defects as early as integrin-dependent Src activation. We decipher the molecular mechanisms involved in vivo by revealing a crucial role of the CD98hc/integrins/Rho guanine nucleotide exchange factor (GEF) leukemia-associated RhoGEF (LARG)/RhoA pathway in skin homeostasis. Finally, we demonstrate that the deregulation of RhoA activation in the absence of CD98hc is also a result of impaired CD98hc-dependent amino acid transports.

scholarly journals Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates ofStreptococcus pneumoniae

2001 ◽  
Vol 45 (12) ◽  
pp. 3517-3523 ◽  
Author(s):  
L. M. Weigel ◽  
G. J. Anderson ◽  
R. R. Facklam ◽  
F. C. Tenover
Keyword(s):  
Amino Acid ◽  
Antimicrobial Agents ◽  
Clinical Isolates ◽  
Fluoroquinolone Resistance ◽  
Cross Resistance ◽  
Genetic Analyses ◽  
High Level ◽  
Susceptibility Profiles ◽  
Level Resistance

ABSTRACT Twenty-one clinical isolates of Streptococcus pneumoniae showing reduced susceptibility or resistance to fluoroquinolones were characterized by serotype, antimicrobial susceptibility, and genetic analyses of the quinolone resistance-determining regions (QRDRs) of gyrA,gyrB, parC, and parE. Five strains were resistant to three or more classes of antimicrobial agents. In susceptibility profiles for gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin, 14 isolates had intermediate- or high-level resistance to all fluoroquinolones tested except gemifloxacin (no breakpoints assigned). Fluoroquinolone resistance was not associated with serotype or with resistance to other antimicrobial agents. Mutations in the QRDRs of these isolates were more heterogeneous than those previously reported for mutants selected in vitro. Eight isolates had amino acid changes at sites other than ParC/S79 and GyrA/S81; several strains contained mutations in gyrB, parE, or both loci. Contributions to fluoroquinolone resistance by individual amino acid changes, including GyrB/E474K, ParE/E474K, and ParC/A63T, were confirmed by genetic transformation of S. pneumoniae R6. Mutations in gyrB were important for resistance to gatifloxacin but not moxifloxacin, and mutation of gyrAwas associated with resistance to moxifloxacin but not gatifloxacin, suggesting differences in the drug-target interactions of the two 8-methoxyquinolones. The positions of amino acid changes within the four genes affected resistance more than did the total number of QRDR mutations. However, the effect of a specific mutation varied significantly depending on the agent tested. These data suggest that the heterogeneity of mutations will likely increase as pneumococci are exposed to novel fluoroquinolone structures, complicating the prediction of cross-resistance within this class of antimicrobial agents.

Sign in / Sign up

Export Citation Format

Share Document